GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Scaled Net Operating Assets

Genscript Biotech (HKSE:01548) Scaled Net Operating Assets : 0.16 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Genscript Biotech's operating assets for the quarter that ended in Dec. 2023 was HK$11,396 Mil. Genscript Biotech's operating liabilities for the quarter that ended in Dec. 2023 was HK$7,232 Mil. Genscript Biotech's Total Assets for the quarter that ended in Jun. 2023 was HK$26,509 Mil. Therefore, Genscript Biotech's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.16.


Genscript Biotech Scaled Net Operating Assets Historical Data

The historical data trend for Genscript Biotech's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Scaled Net Operating Assets Chart

Genscript Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 0.47 0.10 0.11 0.21

Genscript Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 -0.06 0.12 0.13 0.16

Competitive Comparison of Genscript Biotech's Scaled Net Operating Assets

For the Biotechnology subindustry, Genscript Biotech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genscript Biotech's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's Scaled Net Operating Assets falls into.



Genscript Biotech Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Genscript Biotech's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(11396.466-7231.547)/19824.61
=0.21

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=26454.151 - 15057.685
=11396.466

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=10488.155 - 2742.114 - 514.494
=7231.547

Genscript Biotech's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Jun. 2023 )
=(11396.466-7231.547)/26509.386
=0.16

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=26454.151 - 15057.685
=11396.466

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=10488.155 - 2742.114 - 514.494
=7231.547

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genscript Biotech Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Genscript Biotech (HKSE:01548) Business Description

Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Executives
Wang Luquan 2401 A concert party to an agreement to buy shares
Wang Ye 2101 Beneficial owner
Zhang Fangliang 2401 A concert party to an agreement to buy shares
Huang Lili 2202 Interest of your spouse
Hu Zhiyong 2201 Interest of corporation controlled by you
Jin Weihong 2201 Interest of corporation controlled by you
Genscript Corporation 2101 Beneficial owner
Hillhouse Fund V, L.p. 2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Gns Holdings Limited 2101 Beneficial owner
Hillhouse Capital Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines